 Adriaan Van Bokhoven
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 30 | 2015 | 999 | 1.470 |
Why?
| | Carcinoma | 4 | 2011 | 213 | 0.530 |
Why?
| | Prostate | 12 | 2015 | 173 | 0.450 |
Why?
| | Cadherins | 12 | 2007 | 190 | 0.420 |
Why?
| | Cell Line, Tumor | 7 | 2015 | 3185 | 0.350 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2011 | 226 | 0.280 |
Why?
| | Tumor Cells, Cultured | 11 | 2008 | 931 | 0.280 |
Why?
| | Pelvic Pain | 3 | 2015 | 32 | 0.260 |
Why?
| | Finasteride | 2 | 2015 | 34 | 0.220 |
Why?
| | Carcinoma, Renal Cell | 4 | 2008 | 178 | 0.180 |
Why?
| | Biopsy | 2 | 2015 | 1089 | 0.170 |
Why?
| | Cell Lineage | 1 | 2001 | 332 | 0.160 |
Why?
| | Cystitis, Interstitial | 2 | 2015 | 15 | 0.150 |
Why?
| | Receptors, Androgen | 2 | 2014 | 143 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2012 | 503 | 0.150 |
Why?
| | Prostatitis | 2 | 2015 | 18 | 0.140 |
Why?
| | Immunohistochemistry | 8 | 2015 | 1690 | 0.140 |
Why?
| | Male | 38 | 2015 | 63759 | 0.130 |
Why?
| | Androstenedione | 1 | 2015 | 11 | 0.120 |
Why?
| | Urinary Tract | 1 | 2015 | 38 | 0.120 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2008 | 7 | 0.120 |
Why?
| | DNA, Neoplasm | 5 | 2003 | 154 | 0.120 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 41 | 0.110 |
Why?
| | Kidney Neoplasms | 4 | 2008 | 347 | 0.110 |
Why?
| | Proteinuria | 1 | 2014 | 91 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 954 | 0.110 |
Why?
| | Trinucleotide Repeats | 1 | 2014 | 25 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2015 | 161 | 0.110 |
Why?
| | Karyotyping | 3 | 2003 | 99 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2014 | 53 | 0.110 |
Why?
| | Chromosome Aberrations | 3 | 2003 | 140 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 43 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2015 | 1327 | 0.110 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 120 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2014 | 187 | 0.100 |
Why?
| | B7-H1 Antigen | 1 | 2015 | 198 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 164 | 0.100 |
Why?
| | Blotting, Western | 5 | 2012 | 1204 | 0.100 |
Why?
| | Androstane-3,17-diol | 1 | 2012 | 2 | 0.100 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2012 | 14 | 0.100 |
Why?
| | Glucuronides | 1 | 2012 | 18 | 0.100 |
Why?
| | Cell Adhesion | 4 | 2004 | 455 | 0.100 |
Why?
| | Proto-Oncogenes | 1 | 1992 | 29 | 0.100 |
Why?
| | Inflammation | 2 | 2015 | 2748 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 636 | 0.090 |
Why?
| | Cadmium | 1 | 2012 | 67 | 0.090 |
Why?
| | Humans | 48 | 2015 | 129847 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 37 | 0.090 |
Why?
| | Chronic Pain | 1 | 2015 | 253 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2012 | 132 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.090 |
Why?
| | Cell Division | 3 | 2011 | 790 | 0.080 |
Why?
| | Epithelial Cells | 4 | 2012 | 1063 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2015 | 804 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2011 | 307 | 0.080 |
Why?
| | Proteins | 1 | 2014 | 944 | 0.080 |
Why?
| | Clinical Medicine | 1 | 2008 | 21 | 0.070 |
Why?
| | Dogs | 3 | 2011 | 385 | 0.070 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1992 | 431 | 0.070 |
Why?
| | Cell Adhesion Molecules | 2 | 2007 | 173 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 814 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 1 | 1992 | 634 | 0.070 |
Why?
| | Biomedical Research | 1 | 2014 | 640 | 0.070 |
Why?
| | Receptors, Calcitriol | 1 | 2008 | 53 | 0.070 |
Why?
| | Catenins | 1 | 2007 | 4 | 0.070 |
Why?
| | Biomarkers | 3 | 2015 | 3971 | 0.070 |
Why?
| | Microbiota | 1 | 2015 | 734 | 0.070 |
Why?
| | Promoter Regions, Genetic | 4 | 2000 | 1213 | 0.070 |
Why?
| | RNA, Messenger | 5 | 2006 | 2703 | 0.070 |
Why?
| | Osteolysis | 1 | 2006 | 18 | 0.060 |
Why?
| | Bone Development | 1 | 2006 | 50 | 0.060 |
Why?
| | Soybean Proteins | 1 | 2006 | 14 | 0.060 |
Why?
| | Isoflavones | 1 | 2006 | 25 | 0.060 |
Why?
| | Molecular Sequence Data | 11 | 2000 | 2833 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 1993 | 1368 | 0.060 |
Why?
| | Base Sequence | 10 | 2000 | 2142 | 0.060 |
Why?
| | Biomarkers, Tumor | 3 | 2008 | 1161 | 0.060 |
Why?
| | Transplantation, Heterologous | 3 | 2012 | 191 | 0.060 |
Why?
| | Brain Neoplasms | 2 | 2012 | 1149 | 0.060 |
Why?
| | Cloning, Molecular | 6 | 2000 | 524 | 0.060 |
Why?
| | Cytoskeletal Proteins | 3 | 2000 | 147 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 333 | 0.060 |
Why?
| | Urinalysis | 2 | 2015 | 75 | 0.060 |
Why?
| | Chromosomes, Human, Pair 16 | 2 | 1995 | 30 | 0.060 |
Why?
| | Gene Deletion | 2 | 1996 | 380 | 0.060 |
Why?
| | Middle Aged | 11 | 2015 | 31177 | 0.060 |
Why?
| | Aged, 80 and over | 6 | 2015 | 7066 | 0.060 |
Why?
| | Spectral Karyotyping | 1 | 2003 | 5 | 0.050 |
Why?
| | DNA Fingerprinting | 1 | 2003 | 25 | 0.050 |
Why?
| | Bone Neoplasms | 3 | 2012 | 229 | 0.050 |
Why?
| | Chromosomes, Human, Pair 9 | 2 | 2000 | 40 | 0.050 |
Why?
| | DNA Primers | 2 | 2001 | 508 | 0.050 |
Why?
| | Keratins | 1 | 2003 | 175 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2489 | 0.050 |
Why?
| | Prostate-Specific Antigen | 1 | 2003 | 160 | 0.050 |
Why?
| | Blotting, Northern | 6 | 2000 | 196 | 0.050 |
Why?
| | Aged | 9 | 2015 | 22107 | 0.050 |
Why?
| | Nerve Tissue Proteins | 3 | 1993 | 569 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2001 | 379 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2015 | 1160 | 0.050 |
Why?
| | Carrier Proteins | 2 | 1996 | 741 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2015 | 3384 | 0.050 |
Why?
| | Precancerous Conditions | 1 | 2003 | 160 | 0.050 |
Why?
| | Chromosome Mapping | 4 | 1999 | 499 | 0.050 |
Why?
| | Prostatectomy | 2 | 2013 | 103 | 0.050 |
Why?
| | Cytogenetics | 1 | 2001 | 10 | 0.050 |
Why?
| | Genes, Neoplasm | 1 | 2001 | 20 | 0.050 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1033 | 0.040 |
Why?
| | Genes, ras | 1 | 2001 | 95 | 0.040 |
Why?
| | Mice, Nude | 3 | 2011 | 680 | 0.040 |
Why?
| | Activated-Leukocyte Cell Adhesion Molecule | 1 | 2000 | 1 | 0.040 |
Why?
| | Carbonic Anhydrases | 1 | 2000 | 13 | 0.040 |
Why?
| | Neoplasm Proteins | 2 | 2000 | 417 | 0.040 |
Why?
| | Adenocarcinoma | 2 | 2012 | 893 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 493 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2271 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2000 | 169 | 0.040 |
Why?
| | Pituitary Hormones | 2 | 1989 | 16 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 611 | 0.040 |
Why?
| | Risk | 2 | 2012 | 860 | 0.040 |
Why?
| | Parathyroid Hormone-Related Protein | 2 | 2011 | 24 | 0.040 |
Why?
| | Cell Communication | 1 | 2000 | 301 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 316 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 3062 | 0.040 |
Why?
| | Transcription, Genetic | 3 | 2000 | 1416 | 0.040 |
Why?
| | RNA | 3 | 2000 | 877 | 0.040 |
Why?
| | Neoplasm Transplantation | 2 | 2011 | 253 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2724 | 0.040 |
Why?
| | Telomerase | 1 | 2000 | 231 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2000 | 308 | 0.030 |
Why?
| | Prognosis | 3 | 2015 | 3773 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2000 | 230 | 0.030 |
Why?
| | Trans-Activators | 1 | 2000 | 392 | 0.030 |
Why?
| | Restriction Mapping | 4 | 1999 | 74 | 0.030 |
Why?
| | Incidence | 2 | 2015 | 2646 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3089 | 0.030 |
Why?
| | Animals | 12 | 2012 | 35409 | 0.030 |
Why?
| | Schistosomiasis | 1 | 1996 | 47 | 0.030 |
Why?
| | alpha Catenin | 3 | 2000 | 12 | 0.030 |
Why?
| | Transfection | 3 | 2006 | 918 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2015 | 15 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 224 | 0.030 |
Why?
| | Urine | 1 | 2015 | 60 | 0.030 |
Why?
| | Maryland | 1 | 2015 | 46 | 0.030 |
Why?
| | Disease Progression | 3 | 2015 | 2628 | 0.030 |
Why?
| | Anilides | 1 | 2015 | 70 | 0.030 |
Why?
| | DNA | 4 | 2000 | 1406 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2015 | 75 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2015 | 82 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 59 | 0.030 |
Why?
| | Female | 8 | 2015 | 68829 | 0.030 |
Why?
| | Chemical Precipitation | 1 | 2014 | 37 | 0.030 |
Why?
| | Mice | 7 | 2012 | 16983 | 0.030 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 9 | 0.030 |
Why?
| | Genes | 1 | 1995 | 225 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2015 | 137 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 169 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2011 | 610 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 176 | 0.030 |
Why?
| | Amino Acid Sequence | 5 | 2000 | 2057 | 0.030 |
Why?
| | Cell Line | 4 | 1994 | 2780 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 159 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 283 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2014 | 38 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| | Syndrome | 1 | 2014 | 338 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 163 | 0.030 |
Why?
| | Needles | 1 | 2014 | 57 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 92 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 187 | 0.030 |
Why?
| | Binding Sites | 2 | 1997 | 1251 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4896 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2012 | 53 | 0.020 |
Why?
| | Antigens, CD | 1 | 2015 | 487 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 836 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fes | 1 | 1992 | 1 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2045 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 514 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 773 | 0.020 |
Why?
| | Exons | 3 | 1999 | 341 | 0.020 |
Why?
| | Retroviridae | 1 | 1992 | 96 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 51 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2000 | 371 | 0.020 |
Why?
| | Calcium | 2 | 1994 | 1212 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 338 | 0.020 |
Why?
| | Carcinogenicity Tests | 1 | 2011 | 6 | 0.020 |
Why?
| | Neoplasms, Connective Tissue | 1 | 2011 | 3 | 0.020 |
Why?
| | Keratin-8 | 1 | 2011 | 4 | 0.020 |
Why?
| | Keratin-7 | 1 | 2011 | 2 | 0.020 |
Why?
| | Keratin-18 | 1 | 2011 | 10 | 0.020 |
Why?
| | Adenoviridae | 1 | 2012 | 193 | 0.020 |
Why?
| | Phenylbutyrates | 1 | 2011 | 22 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2011 | 22 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 45 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 2011 | 37 | 0.020 |
Why?
| | Boronic Acids | 1 | 2011 | 37 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2011 | 146 | 0.020 |
Why?
| | Adult | 5 | 2015 | 35634 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 38 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1877 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 170 | 0.020 |
Why?
| | Pyrazines | 1 | 2011 | 87 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2011 | 83 | 0.020 |
Why?
| | DNA, Viral | 1 | 1992 | 347 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 399 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 590 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 836 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 1992 | 482 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 941 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 650 | 0.020 |
Why?
| | Cell Cycle | 1 | 2012 | 583 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1847 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2010 | 187 | 0.020 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 1989 | 56 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2012 | 4102 | 0.020 |
Why?
| | Silymarin | 1 | 2010 | 199 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1995 | 2545 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1724 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 1045 | 0.020 |
Why?
| | Primaquine | 1 | 1988 | 7 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 310 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 51 | 0.020 |
Why?
| | Risk Factors | 2 | 2014 | 9801 | 0.020 |
Why?
| | Sequence Alignment | 2 | 2000 | 331 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 4935 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2000 | 778 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1201 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2008 | 204 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 1996 | 27 | 0.020 |
Why?
| | Antioxidants | 1 | 2010 | 558 | 0.020 |
Why?
| | Introns | 2 | 1999 | 249 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1988 | 216 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1996 | 66 | 0.020 |
Why?
| | Luciferases | 1 | 2006 | 147 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2007 | 647 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2006 | 138 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2006 | 266 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 3269 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2006 | 176 | 0.020 |
Why?
| | Mutation | 1 | 1996 | 3706 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 851 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2378 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2010 | 1264 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1501 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1087 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 7158 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1951 | 0.010 |
Why?
| | Androgens | 1 | 2003 | 177 | 0.010 |
Why?
| | RNA, Neoplasm | 2 | 1992 | 82 | 0.010 |
Why?
| | Gene Library | 2 | 1992 | 115 | 0.010 |
Why?
| | DNA Footprinting | 1 | 2000 | 33 | 0.010 |
Why?
| | Plasmids | 2 | 1992 | 360 | 0.010 |
Why?
| | Fibroblast Growth Factor 8 | 1 | 2000 | 27 | 0.010 |
Why?
| | Lentivirus | 1 | 2000 | 53 | 0.010 |
Why?
| | Scintillation Counting | 1 | 2000 | 3 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 2000 | 25 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2000 | 159 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2000 | 47 | 0.010 |
Why?
| | Aging | 1 | 2010 | 1774 | 0.010 |
Why?
| | Stromal Cells | 1 | 2000 | 106 | 0.010 |
Why?
| | Carbonic Anhydrase IX | 1 | 2000 | 4 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2000 | 124 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 838 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 70 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 2 | 1992 | 188 | 0.010 |
Why?
| | Desmoplakins | 1 | 2000 | 19 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2000 | 224 | 0.010 |
Why?
| | Prostatic Intraepithelial Neoplasia | 1 | 1999 | 11 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 301 | 0.010 |
Why?
| | Rats | 3 | 1993 | 5487 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2000 | 220 | 0.010 |
Why?
| | Neuroendocrine Secretory Protein 7B2 | 2 | 1989 | 2 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 45 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 170 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2000 | 312 | 0.010 |
Why?
| | Organ Specificity | 1 | 2000 | 295 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2000 | 393 | 0.010 |
Why?
| | Diet | 1 | 2006 | 1212 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2000 | 585 | 0.010 |
Why?
| | Helix-Loop-Helix Motifs | 1 | 1997 | 12 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 796 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2000 | 204 | 0.010 |
Why?
| | beta Catenin | 1 | 2000 | 224 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1997 | 24 | 0.010 |
Why?
| | Base Composition | 1 | 1997 | 76 | 0.010 |
Why?
| | Dinucleoside Phosphates | 1 | 1997 | 26 | 0.010 |
Why?
| | Cell Survival | 1 | 2000 | 1086 | 0.010 |
Why?
| | United States | 1 | 2014 | 13913 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1997 | 179 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 316 | 0.010 |
Why?
| | Egypt | 1 | 1996 | 10 | 0.010 |
Why?
| | Netherlands | 1 | 1996 | 77 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1311 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1989 | 2344 | 0.010 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 10 | 0.010 |
Why?
| | Sequence Homology | 1 | 1994 | 39 | 0.010 |
Why?
| | TATA Box | 1 | 1994 | 24 | 0.010 |
Why?
| | DNA Probes | 1 | 1994 | 60 | 0.010 |
Why?
| | Chickens | 1 | 1994 | 188 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1994 | 296 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 1995 | 177 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 484 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 151 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2000 | 1441 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1993 | 216 | 0.010 |
Why?
| | Epitopes | 1 | 1993 | 474 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 406 | 0.010 |
Why?
| | Kidney | 1 | 1998 | 1383 | 0.010 |
Why?
| | Biological Evolution | 1 | 1994 | 435 | 0.010 |
Why?
| | Transcription Factors | 1 | 1997 | 1645 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1989 | 169 | 0.000 |
Why?
| | Asialoglycoprotein Receptor | 1 | 1988 | 6 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1988 | 270 | 0.000 |
Why?
| | Protein Conformation | 1 | 1988 | 861 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1988 | 636 | 0.000 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 1050 | 0.000 |
Why?
| | Adolescent | 1 | 1998 | 20451 | 0.000 |
Why?
|
|
Van Bokhoven's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|